Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology. 1960;10:107–11.

Article  PubMed  CAS  Google Scholar 

Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008;48:685–7.

Article  PubMed  Google Scholar 

Dixon RM, Meire HB, Evans DH, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia. 1997;17:639–46.

Article  PubMed  CAS  Google Scholar 

Usha Rani P, Naidu MUR, Ramesh Kumar Rao T, et al. Sumatriptan delays paracetamol absorption in migraine patients. Clin Drug Invest. 1996;11(5):300–4.

Article  Google Scholar 

Seaber EJ, Ridout G, Layton G, et al. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol. 1997;53(3–4):229–34.

Article  PubMed  CAS  Google Scholar 

Srinivasu P, Rambhua D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol. 2000;40:99–104.

Article  PubMed  CAS  Google Scholar 

Srinivas NR, Shyu WC, Upmalis D, et al. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. J Clin Pharmacol. 1995;35(4):432–7.

Article  PubMed  CAS  Google Scholar 

Vachharajani NN, Shyu W-C, Nichola PS, et al. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Cephalalgia. 2002;22:282–7.

Article  PubMed  CAS  Google Scholar 

Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine suffers. Br J Clin Pharmacol. 1983;166:95–699.

Google Scholar 

Veronese L, Gillotin C, Marion-Gallois R, et al. Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan in healthy volunteers. Clin Drug Invest. 1997;14:217–20.

Article  CAS  Google Scholar 

Buchan P, Wade A, Ward C, et al. Frovatriptan: a review of drug–drug interactions. Headache. 2002;42(Suppl 2):S63–73.

Article  PubMed  Google Scholar 

Tfelt-Hansen P, Rolan P. β-adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The headaches. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 519–28.

Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol. 1991;32:581–4.

Article  PubMed  CAS  Google Scholar 

Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90). Cephalalgia. 1997;17:21.

PubMed  Google Scholar 

Goldberg MR, Sciberras D, De Smet M, et al. Influence of β-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT_IB/ID agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol. 2001;52:69–76.

Article  PubMed  CAS  Google Scholar 

Fleishaker JC, Sisson TA, Carel BJ, et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia. 2001;21:61–5.

Article  PubMed  CAS  Google Scholar 

electronic Medicines Compendium (eMC). Relpax 20 mg and 40 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/8195/SPC/RELPAX+20mg+and+40mg+Film-Coated+Tablets. [Accessed 2012 May 31].

Fowler PA, Lacey LF, Keene ON, et al. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia. 1991;11(Suppl. 11):228–9.

Google Scholar 

Seaber EJ, Gillotin C, Mohanlal R, et al. Lack of an interaction between pizotifen and the novel antimigraine compound zolmitriptan in healthy volunteers. Clin Drug Invest. 1997;14:221–5.

Article  CAS  Google Scholar 

Van Hecken AM, Depré M, de Schepper PJ, et al. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol. 1992;34:82–4.

Article  PubMed  Google Scholar 

Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000;67:498–503.

Article  PubMed  CAS  Google Scholar 

MacLennan SJ, Martin GR. Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction. Naunyn Schmiedebergs Arch Pharmacol. 1990;342(2):120–9.

Article  PubMed  CAS  Google Scholar 

Liston H, Bennett L, Usher B Jr, et al. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med. 1999;159(5):511–3.

Article  PubMed  CAS  Google Scholar 

Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.

Article  PubMed  CAS  Google Scholar 

Tepper S, Allen C, Sanders D, et al. Coprescription of triptans with potentially interacting medications: a cohort study involving 240268 patients. Headache. 2003;43:44–8.

Article  PubMed  Google Scholar 

Boutilier ASW, Gardner DM. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report. J Clin Pharm Ther. 2003;28:69–72.

Article  PubMed  CAS  Google Scholar 

Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug–drug interactions. Headache. 2007;47:266–9.

Article  PubMed  Google Scholar 

Joffe RT, Sokolov STH. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand. 1997;95:551–2.

Article  PubMed  CAS  Google Scholar 

Smith DA, Cleary EW, Watkins S, et al. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther. 1998;36(6):301–5.

PubMed  CAS  Google Scholar 

Fleishaker JC, Ryan KK, Carel BJ, et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol. 2001;41:217–23.

Article  PubMed  CAS  Google Scholar 

Kempsford RD, Lacey LF, Thomas M, et al. The effect of alcohol on the pharmacokinetic profile of oral sumatriptan [abstract]. Fundam Clin Pharmacol. 1991;5:470.

Google Scholar 

electronic Medicines Compendium (eMC). Naramig tablets 2.5 mg: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/759/SPC/Naramig+Tablets+2.5mg/ [Accessed 2012 Jun 06].

Shadle CR, Liu G, Goldberg MR. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. J Clin Pharmacol. 2000;40(3):309–15.

Article  PubMed  CAS  Google Scholar 

Van Haarst AD, Van Gerven JMA, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999;48(2):190–6.

Article  PubMed  Google Scholar 

Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001;51:437–41.

Article  PubMed  CAS  Google Scholar 

Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol. 2003;43:423–7.

Article  PubMed  CAS  Google Scholar 

Moore KHP, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther. 2002;24(4):583–94.

Article  PubMed  CAS  Google Scholar 

Dixon R, French S, Kemp J, et al. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers. Clin Drug Investig. 1998;15(6):515–22.

Article  PubMed  CAS  Google Scholar 

Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91(2):321–6.

Article  PubMed  CAS  Google Scholar 

Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689–723.

Article  PubMed  CAS  Google Scholar 

Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46(1):57–63.

Article  PubMed  Google Scholar 

The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral dose-defining study. Eur Neurol. 1991;31(5):300–5.

Article  Google Scholar 

Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs. 2001;15(2):105–18.

Article  PubMed  CAS  Google Scholar 

GlaxoSmithKline. Clinical study register [online]. Available from URL: http://www.gsk-clinicalstudyregister.com/ [Accessed 2012 Aug 28].

Centre for Drug Evaluation and Research. Relpax: clinical pharmacology and biopharmaceutics review of original US submission [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf [Accessed 2012 Aug 28].